Please login to the form below

Not currently logged in
Email:
Password:

Pfizer drives oncology R&D growth

Pfizer is to run seven new clinical studies into liver, renal cell carcinoma, lung and prostate cancers
Pfizer is to run seven new clinical studies into liver, renal cell carcinoma, lung and prostate cancers.

These studies are part of Pfizer's growing oncology research and development (R&D) programme, which has increased by 400 per cent since 2003. Dedicating just under a quarter of its overall R&D budget to oncology, the company currently has 22 compounds in 232 clinical studies.

"We are seeing our sustained efforts in oncology mature as our development programmes continue to advance into late-stage clinical trials," said Dr Charles Baum, vice-president of Pfizer Global Research and Development.

In 2008 alone, Pfizer has presented 299 new agents at the American Society of Clinical Oncology (ASCO) meeting. The company has also started two phase III studies and expects to start the remaining five by the end of the year.

A dedicated business unit, focused on oncology within Pfizer's worldwide pharmaceutical group, was established in March 2008. The unit will accelerate the launches of new oncology agents and focus research efforts on cancers common in Asia such as those of the liver, oesophagus and nasopharynx.

4th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics